May 15, 2017| BiomX Ltd., an Israeli microbiome therapeutics company, announced today that it has raised $24 million in a Series A funding round. The round was led by OrbiMed, Johnson & Johnson Innovation – JJDC, Inc. and Takeda Ventures, Inc. with participation from Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors. BiomX, previously named MBcure, was founded in the FutuRx Ltd. incubator, with the support of the Israel Innovation Authority.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments